Ergomed has completed recruitment in its Phase IIb trial evaluating PeproStat™ six months ahead of schedule. The group announced in June that it had reached recruitment mid-point quicker than originally anticipated with top line data expected in Q4 2017, earlier than the original Q1 2018. This highlights Ergomed’s ability to recruit patients successfully and undertake trials efficiently. PeproStat™ offers a differentiated approach to current products in the haemostat market in that it is manufac ....
24 Jul 2017
N+1 Singer - Ergomed - PeproStat™ Phase IIb fully recruited; top line data Q4 2017
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Ergomed - PeproStat™ Phase IIb fully recruited; top line data Q4 2017
- Published:
24 Jul 2017 -
Author:
Sheena Berry -
Pages:
3
Ergomed has completed recruitment in its Phase IIb trial evaluating PeproStat™ six months ahead of schedule. The group announced in June that it had reached recruitment mid-point quicker than originally anticipated with top line data expected in Q4 2017, earlier than the original Q1 2018. This highlights Ergomed’s ability to recruit patients successfully and undertake trials efficiently. PeproStat™ offers a differentiated approach to current products in the haemostat market in that it is manufac ....